QUT scientists have discovered a promising new therapy for a deadly type of endometrial cancer that has a poor prognosis if the cancer spreads or returns after initial treatment, a plight that affects 15-20 per cent of endometrial cancer patients.
- Testing of new drug inhibited uterine tumour cell growth in lab and mice models
- The drug blocks the receptor of the growth factor in tumours that is associated with a low survival rate
- The inhibitor also reduced the tumours blood vessel formation
Dr Asmerom Sengal and Associate Professor Pamela Pollock from QUT’s School of Biomedical Sciences, published their research in Nature Precision Oncology with a recommendation that the strength of their findings indicated they should proceed to patient trials.
Dr Asmerom said endometrial cancer confined within the uterus could be cured with surgery however, if it had spread to the abdomen and other organs patients had limited treatment options.
“Previously, we found women with endometrial cancer who have an incorrect growth factor receptor called fibroblast growth factor receptor 2c (FGFR2c) on the tumour cell surface have a poor survival rate,” Dr Asmerom said.
“For this study, we developed organoids – three-dimensional miniature tumours grown from patients’ endometrial cancer cells in a hydrogel to enable us to study the complexity of the tumour structure and genetics.
“We found that endometrial cancer organoids with activated (or turned on) FGFR2c were blocked with an FGFR inhibitor drug and the organoids' growth was shattered and they died.
“These findings were further validated by blocking of ‘turned-on’ FGFR2c in patient-derived xenografts (PDXs) - endometrial cancers implanted in mice - with the same FGFR2c inhibitor which resulted in significant tumour growth inhibition, and the treated mice showed a remarkable increase in survival.
Dr Asmerom said an interesting finding was that the endometrial cancer patient xenografts which harboured activated FGFR2c were treated with FGFR inhibitor for seven days and demonstrated remarkable reduction in tumour blood vessel formation and the immune cells (M2-macrophages) that prevent our immune system from killing cancer cells.
“Collectively, the study supports the initiation of a clinical trial combining a FGFR inhibitor with immunotherapy and this opens a new opportunity for personalised care in women with deadly endometrial cancer,” he said.
Endometrial cancer PDX-derived organoids (PDXOs) and PDXs with FGFR2c isoform 2 expression are sensitive to FGFR inhibition was published in Nature Precision Oncology.
Image: left, Dr Asmerom Sengal, Professor Pamela Pollock.
QUT Media contact:
Niki Widdowson, 07 3138 2999, n.widdowson@qut.edu.au
After hours: 0407 585 901, media@qut.edu.au
